Bank of America
ZNTL icon

Bank of America’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Bank of America’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.65M Sell
1,132,294
-234,960
-17% -$607K ﹤0.01% 3923
2025
Q4 		$1.85M Sell
1,367,254
-181,527
-12% -$264K ﹤0.01% 4126
2025
Q3 		$2.34M Buy
1,548,781
+835,466
+117% +$1.25M ﹤0.01% 4690
2025
Q2 		$827K Sell
713,315
-416,777
-37% -$550K ﹤0.01% 5414
2025
Q1 		$1.8M Buy
1,130,092
+914,093
+423% +$1.97M ﹤0.01% 4767
2024
Q4 		$654K Sell
215,999
-559,537
-72% -$1.83M ﹤0.01% 5342
2024
Q3 		$2.85M Buy
775,536
+267,303
+53% +$971K ﹤0.01% 4256
2024
Q2 		$2.08M Buy
508,233
+32,277
+7% +$360K ﹤0.01% 4418
2024
Q1 		$7.5M Sell
475,956
-242,687
-34% -$3.34M ﹤0.01% 3256
2023
Q4 		$10.9M Buy
718,643
+485,680
+208% +$7.09M ﹤0.01% 2798
2023
Q3 		$4.67M Sell
232,963
-32,521
-12% -$825K ﹤0.01% 3475
2023
Q2 		$7.49M Sell
265,484
-34,806
-12% -$835K ﹤0.01% 2998
2023
Q1 		$5.16M Buy
300,290
+59,950
+25% +$1.21M ﹤0.01% 3518
2022
Q4 		$4.84M Buy
240,340
+118,205
+97% +$2.54M ﹤0.01% 3415
2022
Q3 		$2.65M Sell
122,135
-187,332
-61% -$5.12M ﹤0.01% 4030
2022
Q2 		$8.7M Buy
309,467
+25,219
+9% +$668K ﹤0.01% 2832
2022
Q1 		$13.1M Buy
284,248
+86,859
+44% +$4.69M ﹤0.01% 2593
2021
Q4 		$16.6M Buy
197,389
+113,038
+134% +$8.75M ﹤0.01% 2404
2021
Q3 		$5.62M Buy
84,351
+2,524
+3% +$146K ﹤0.01% 3450
2021
Q2 		$4.35M Sell
81,827
-8,715
-10% -$467K ﹤0.01% 3647
2021
Q1 		$3.93M Buy
90,542
+42,478
+88% +$1.83M ﹤0.01% 3638
2020
Q4 		$2.5M Buy
48,064
+18,132
+61% +$818K ﹤0.01% 3751
2020
Q3 		$979K Buy
29,932
+12,993
+77% +$455K ﹤0.01% 4227
2020
Q2 		$814K Buy
+16,939
New +$650K ﹤0.01% 4265

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Bank of America's ZNTL Position: Q1 2026 in Review

Bank of America reduced its Zentalis Pharmaceuticals (ZNTL) stake by 17% in Q1 2026, selling an estimated $607K and leaving 1,132,294 shares worth $2.65M. The position accounts for ﹤0.01% of the portfolio, ranked #3923.

Bank of America first reported a position in ZNTL in Q2 2020 and has held it in 24 quarters since. The position peaked at $16.6M in Q4 2021. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Bank of America held 1,132,294 shares of Zentalis Pharmaceuticals worth $2.65M as of Q1 2026.
  • Bank of America sold 234,960 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $607K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3923 holding.
  • Bank of America first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • Bank of America's Zentalis Pharmaceuticals position peaked at $16.6M in Q4 2021.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.